Navigation Links
Other highlights in the Feb. 26 JNCI
Date:2/26/2008

No Additional Benefit Found for Personalized Intervention to Promote Regular Mammography Screening

Two different interventions did not significantly increase regular mammography screening in a large randomized study.

Behavioral interventions, such as personalized mailings, have been reported to increase one-time cancer screening. However, few studies have examined the impact of behavioral interventions on regular or on-going participation in screening exams.

Sally Vernon, Ph.D., of the University of Texas School of Public Health in Houston and colleagues assigned 5,500 female veterans to one of three interventions designed to encourage annual mammograms - a baseline survey plus a targeted mailing, a baseline survey plus a targeted mailing that was tailored to individual participants, or the baseline survey alone. The investigators then looked to see how many women in each group had completed two mammograms as recommended during the three-year follow-up period.

Neither the targeted mailing nor the targeted and tailored mailing was associated with a statistically significant increase in the percentage of women who had regular mammograms compared to the survey-only group.

Noting that two other trials have recently reported similar findings, the authors write, Collectively, these findings and ours provide little support for an additional benefit of using tailored interventions, either mailed or by telephone, to increase regular mammography screening.

In an accompanying paper by Deborah del Junco, Ph.D., of the University of Texas Health Science Center in Houston and colleagues, the researchers report that the results of the intervention trial are likely to be internally valid and applicable to the larger population. They assessed the validity of the trial by including two additional control groups in the study design and by comparing the characteristics of study participants with those of nonparticipants. The investigators found that the baseline survey by itself did not influence subsequent mammography screening rates. In addition, they found that mammography rates actually decreased in the final study year in the veteran population.

Similar rates of mammography coverage and compliance in the US female population and the decline reported for the US female population between 2000 and 2005 lend additional support to the generalizability of our results, the authors write.

Contact:
Article #1: Sally Vernon, Sally.W.Vernon@uth.tmc.edu, (713) 500-9760
Article #2: Deborah J. del Junco, Deborah.J.DelJunco@uth.tmc.edu, (713) 500-7902


Viral DNA Testing Is Cost-Effective for Cervical Cancer Screening

Adjustment of cervical cancer screening protocols as a woman ages may be cost-effective, regardless of whether she has been vaccinated against the human papillomavirus (HPV) that causes cervical cancer.

Since the release of cervical cancer screening guidelines in 2001 and 2003, more data has become available showing that HPV DNA-based testing is more effective in detecting precancerous changes in a womans cervix than standard cytology (Pap) tests. With these data and the development of a vaccine that prevents two types of HPV infection, analyses are needed that estimate both the effectiveness and cost of different screening strategies for U.S. women.

Using information about the frequency with which girls of different ages become infected with HPV and the likelihood that a persistent infection will lead to cancer, Sue J. Goldie, M.D., of Harvard School of Public Health in Boston and colleagues mathematically modeled the impact of each available screening technique in vaccinated and unvaccinated women. While a number of acceptable strategies were identified, the researchers found that the most cost-effective screening protocols for both vaccinated and unvaccinated women included cytology during the early part of a womans life, followed by HPV DNA-based screening after age 30. This strategy differs from most commonly used screening practices.

The investigators emphasized that the frequency of screening could be reduced in vaccinated individuals and the switch to DNA-based screening delayed by five years, relative to unvaccinated women. The researchers estimated that cervical cancer risk could be reduced by an additional 30 percent in future generations of American women provided there is high vaccine coverage in preadolescent girls, continued screening in vaccinated and unvaccinated women, and targeted efforts to recruit and screen women with historically poor access to cervical cancer prevention.

Our findings indicate that it may be worthwhile to consider strategies that differ according to age and vaccination status and to revisit screening options recommended for older women, the authors write.

In an accompanying editorial, Nancy Kiviat, M.D., of Harborview Medical Center in Seattle, and colleagues write The analyses presented [here] will undoubtedly support the urgently needed development of screening recommendations for the immediate future.

Contact:
Article: Robin Herman, rherman@hsph.harvard.edu, (617) 432-4388 or Todd Datz, tdatz@hsph.harvard.edu, (617) 432-3952
Editorial: Nancy Kiviat, nbk@u.washington.edu, (206) 731-3145


Interleukin Plays a Role in Ovarian Cancer Growth

Patients whose tumors produced high levels of interleukin-8 (IL-8) protein had a worse outcome than those with less IL-8. Blocking expression of IL-8 in mouse models of ovarian cancer slowed tumor growth by reducing blood vessel growth.

IL-8 expression is elevated in many human tumors. Previous work indicated that the protein stimulates tumor growth, blood vessel development, and metastasis in animal models. Suppressing its activity with antibody therapy slowed tumor growth in those models.

In the current study, Anil Sood, M.D., of the University of Texas M. D. Anderson Cancer Center in Houston and colleagues tested 102 human ovarian cancer tumor samples for IL-8 expression. Of those, 43 (42 percent) had high levels of the protein and 69 (58 percent) had low or no IL-8 expression. The researchers found that the women whose tumors had higher levels of IL-8 were more likely to have advanced disease and poorer survival.

When the team used small-interfering RNAs to block IL-8 gene expression in animal models of ovarian cancer, they saw that tumor growth was substantially reduced. The slowed growth appeared to be due to less blood vessel development.

Our findings suggest that IL-8 may be a potential therapeutic target in ovarian cancer, the authors write.

Contact: Scott Merville, sdmervil@mdanderson.org, (713) 792-0661


Also in February 26 JNCI:
http://www.eurekalert.org/emb_releases/2008-02/jotn-sn022108.php
http://www.eurekalert.org/emb_releases/2008-02/jotn-cp022108.php


'/>"/>

Contact: Liz Savage
jncimedia@oxfordjournals.org
301-841-1287
Journal of the National Cancer Institute
Source:Eurekalert

Related medicine news :

1. Kristalose(R) Offers Prescription Alternative to MiraLAX(R) and Other PEG 3350 Products
2. Autisms origins: Mothers antibody production may affect fetal brain
3. Drugs, Doctors and Death: Heath Ledger Becomes Another Victim
4. Breakfast BREAKS and Teen Music Phenomenon the Jonas Brothers Team Up to Raise Awareness about the Importance of Eating Breakfast
5. Another way to grow blood vessels
6. Study identifies another strategy for normalizing tumor blood supply
7. Hormone refractory prostate cancers more likely to spread to other organs
8. Varian Medical Systems Announces Symposia on RapidArc Technology for Faster, More Precise Radiotherapy Treatments
9. Chemotherapy After Breast Cancer Surgery Effective for Older Women, Too
10. Enzyme structure reveals new drug targets for cancer and other diseases
11. Other highlights in the Feb. 12 JNCI
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... (PRWEB) , ... June 27, ... ... in the patient payment industry today announced its strategic partnership with Connance, ... system workflows. , The two companies’ proven, proprietary technology combine to provide ...
(Date:6/26/2016)... ... June 26, 2016 , ... On June 10-11, 2016, A Forever ... Cereal Festival and World’s Longest Breakfast Table in Battle Creek, MI, where the rehabilitation ... as home to some of the world’s leading providers of cereal and other breakfast ...
(Date:6/26/2016)... , ... June 26, 2016 , ... ... once they have been diagnosed with endometriosis. These women need a treatment plan ... require a comprehensive approach that can help for preservation of fertility and ultimately ...
(Date:6/25/2016)... ... ... "With 30 hand-drawn hand gesture animations, FCPX users can easily customize each ... Film Studios. , ProHand Cartoon’s package transforms over 1,300 hand-drawn pictures into hand ... select a ProHand generator and drag it above media or text in the Final ...
(Date:6/25/2016)... ... June 25, 2016 , ... On Friday, June 10, Van Mitchell, ... at Work award to iHire in recognition of their exemplary accomplishments in worksite health ... annual Maryland Workplace Health & Wellness Symposium at the BWI Marriott in Linthicum Heights. ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... , June 24, 2016 Research ... World Market for Companion Diagnostic Tests" report to their ... Market for Companion Diagnostics The World Market ... and personalized medicine diagnostics. Market analysis in the report includes ... Test Market (In Vitro Diagnostic Kits) by Region (N. America, ...
(Date:6/24/2016)... 24, 2016  Arkis BioSciences, a leading innovator ... more durable cerebrospinal fluid treatments, today announced it ... funding is led by Innova Memphis, followed by ... private investors.  Arkis, new financing will accelerate the ... market release of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... 2016 Research and Markets has ... by Type (Organic Chemical (Sugar, Petrochemical, Glycerin), Inorganic Chemical), ... Parenteral) - Global Forecast to 2021" report to ... The global pharmaceutical excipients market is projected to reach ... 6.1% in the forecast period 2016 to 2021. ...
Breaking Medicine Technology: